FDA Approves Bimekizumab for Three Rheumatologic Conditions ...Middle East

Medscape - News
The drug is the first and only dual IL-17A and IL-17F inhibitor approved to treat four chronic immune-mediated inflammatory diseases. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves Bimekizumab for Three Rheumatologic Conditions )

Apple Storegoogle play

Also on site :